MDGL

Madrigal Pharmaceuticals, Inc. [MDGL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MDGL Stock Summary

Top 10 Correlated ETFs

MDGL

Top 10 Correlated Stocks

MDGL

In the News

MDGL Financial details

Company Rating
-
Market Cap
4.97B
Income
-374.53M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
376
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-12.56
Forward P/E
-
PEG
-8.71
P/S
-
P/B
197.6
P/C
-
P/FCF
-15.49
Quick Ratio
2.33
Current Ratio
2.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-19.99
EPS next Y
-
EPS next Q
-
EPS this Y
14.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
6.37%
-
-
-
-
SMA20
-3.18%
SMA50
-14.63%
SMA100
-5.77%
Inst Own
-
Inst Trans
-
ROA
-147%
ROE
-296%
ROC
-2.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
119.76-322.67
52W High
-8.21%
52W Low
+148.38%
RSI
55.21
Rel Volume
0.47
Avg Volume
576.5K
Volume
270.71K
Perf Week
5.82%
Perf Month
-9.8%
Perf Quarter
0.96%
Perf Half Y
-3.58%
-
-
-
-
Beta
-0.437
-
-
Volatility
8.75%, 12.07%
Prev Close
-0.55%
Price
295.57
Change
1.26%

Something similar

Top by Market Cap
FXAIX
TSLA
MIX.JO
NVDA
LLY.DE
Top Correlated ETFs
SGIL.L
CRPS.L
IHCU.L
XLVP.L
EMIG.L
Top Correlated Stocks
FAF
URGN
SKL.L
0JZS.L
PEN.L
Similar Market Cap
0I5O.L
600343.SS
EO.PA
SFB
002501.SZ

Company Profile

Healthcare Biotechnology
  • Volume Average 576.5K
  • Market Capitalization 4.97B
  • Employee 376
  • CEO Mr. William J. Sibold
  • Headquarters West Conshohocken,PA,US
  • IPO Date 2007-02-06
  • Website https://www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.